Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 17/20 | 1.00 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.64 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.64 |
| ▸ | PDE4A | P27815 | 5/20 | 0.62 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.62 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.62 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.62 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.57 |
| ▸ | PDE2A | O00408 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10263001 | 0.80 | PDE5A (0.68) | PDE5APDE3BPDE3APDE4APDE4B | |
| SCHEMBL16503589 | 0.80 | PDE5A (0.66) | PDE5APDE3BPDE3APDE4APDE4B | |
| SCHEMBL235355 | 0.79 | PDE5A (0.67) | PDE5APDE3BPDE3APDE4APDE4B | |
| SCHEMBL7874358 | 0.76 | PDE4A (1.00) | PDE5APDE3BPDE3APDE4APDE4B | |
| SCHEMBL715378 | 0.76 | PDE5A (1.00) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7448642 | 0.76 | PDE5A (0.83) | PDE5APDE3BPDE3APDE4APDE4B | |
| SCHEMBL714965 | 0.75 | PDE5A (0.82) | PDE5APDE3BPDE3APDE4APDE4B | |
| SCHEMBL20841478 | 0.74 | PDE5A (0.78) | PDE5APDE3BPDE3APDE4APDE4B | |
| SCHEMBL10201625 | 0.74 | PDE5A (0.78) | PDE5APDE3BPDE3APDE4APDE4B | |
| SCHEMBL10201496 | 0.73 | PDE5A (1.00) | PDE5APDE3BPDE3APDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10010553-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-10010553-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-20160375028-A1 | ORGANIC COMPOUNDS | FIENBERG ALLEN A (US) | 2016-12-29 | — | — | US | disclosed |
| US-9468637-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-9468637-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-20160038494-A1 | NOVEL COMBINATION | INTRA-CELLULAR THERAPIES, INC. | 2016-02-11 | — | — | US | disclosed |
| US-9198924-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-9198924-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-9006258-B2 | Method of treating female sexual dysfunction with a PDE1 inhibitor | INTRA-CELLULAR THERAPIES, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-9006258-B2 | Method of treating female sexual dysfunction with a PDE1 inhibitor | INTRA-CELLULAR THERAPIES, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-20120053190-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC | 2012-03-01 | — | — | US | disclosed |
| US-20120053190-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC | 2012-03-01 | — | — | US | disclosed |
| US-20100323997-A1 | NOVEL USES | INTRACELLULAR THERAPIES, INC. (US) | 2010-12-23 | — | — | US | disclosed |
| US-20100323997-A1 | NOVEL USES | INTRACELLULAR THERAPIES, INC. (US) | 2010-12-23 | — | — | US | disclosed |
| US-20100087450-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2010-04-08 | — | — | US | disclosed |
| US-20100087450-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053190-A1 | ORGANIC COMPOUNDS | PDE5A, PDE4A, PDE3A | PDE5A 1/4885PDE3B 7/4885PDE3A 3/4885 |
| US-20160038494-A1 | NOVEL COMBINATION | PDE5A, PDE2A, PDE3A | PDE5A 1/4885PDE3B 5/4885PDE3A 3/4885 |
| US-10010553-B2 | Organic compounds | PDE5A, PDE4A, PDE3A | PDE5A 1/4885PDE3B 7/4885PDE3A 3/4885 |
| US-20160375028-A1 | ORGANIC COMPOUNDS | PDE5A, PDE4A, PDE3A | PDE5A 1/4885PDE3B 7/4885PDE3A 3/4885 |
| US-20100087450-A1 | ORGANIC COMPOUNDS | PDE3A, PDE5A, PDE2A | PDE5A 2/4885PDE3B 4/4885PDE3A 1/4885 |
| US-20100323997-A1 | NOVEL USES | PDE5A, PDE2A, PDE3A | PDE5A 1/4885PDE3B 5/4885PDE3A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.